Published on 16 Apr 2024 on Zacks via Yahoo Finance
bluebird (BLUE) Underperforms Industry YTD Amid Challenges
bluebird bio’s BLUE shares have lost 25.4% year to date compared with the industry’s decline of 7.9%.
As of now, the going is challenging for bluebird. While the approval of its three gene therapies bodes well, the uptake of the same has not gained traction as expected.
